pharmiweb.com today archive

Roche is showing good sales growth in the first Quarter of 2012:

Group sales rise 2%, Diagnostics sales grow 4%.

It also has approvals for two new, first-in-class skin cancer medicines: Zelboraf (melanoma, EU) and Erivedge (basal cell carcinoma, US) as well as five out of five late-stage clinical studies with positive results.

Group and Pharmaceuticals sales expected to grow at low to mid-single-digit rates; Diagnostics to grow above the market; target of high single-digit Core Earnings per Share growth.

Roche CEO Severin Schwan commenting on the Group’s first quarter 2012 performance: “With sales advancing 2% in the first three months, we remain on track to achieve our targets for the full-year. After the rapid approvals of Zelboraf and Erivedge we can now make these innovative medicines available to patients suffering from severe forms of skin cancer. The ongoing positive newsflow on our product pipeline underscores our growth prospects for the coming years: since the beginning of the year we have announced positive results from five out of five key late-stage clinical trials.”

• Roche News